Virax Biolabs Group Limited (NASDAQ:VRAX – Get Free Report) was down 0% during mid-day trading on Monday . The stock traded as low as $0.4734 and last traded at $0.4910. Approximately 27,163 shares were traded during trading, a decline of 86% from the average daily volume of 189,532 shares. The stock had previously closed at $0.4912.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Virax Biolabs Group in a research note on Tuesday, October 14th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $3.00.
Get Our Latest Stock Analysis on Virax Biolabs Group
Virax Biolabs Group Price Performance
Virax Biolabs Group Company Profile
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.
Featured Articles
- Five stocks we like better than Virax Biolabs Group
- Where to Find Earnings Call Transcripts
- Whirlpool’s Worst May Be Over—Upside Opportunity Ahead
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- These 3 Beaten-Down Stocks Could Be Your Best Buying Opportunity This Quarter
- 3 Stocks to Consider Buying in October
- How Does D-Wave Stack Up to Quantum Rivals After Earnings Season?
Receive News & Ratings for Virax Biolabs Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virax Biolabs Group and related companies with MarketBeat.com's FREE daily email newsletter.
